Biogen (BIIB) Q2 2026 Earnings Call Transcript
Biogen (NASDAQ:BIIB) reported Q2 2026 revenue of $2.7B, up 3% year over year. GAAP EPS was $0.66, down from $4.33; non-GAAP EPS was $3.60, down 34%. Growth portfolio revenue rose to $1.1B. Full-year revenue guidance was revised to a mid-single-digit increase, and non-GAAP EPS guidance is $12.00 to $13.00. Net debt was $6.8B after the Apellis deal.
How this was made
The 30-second read
Why it matters
Traders can update models for 2026 revenue and non-GAAP EPS ranges, reassess cash generation and leverage post-Apellis, and reprice pipeline risk given the pause of BIIB091 in relapsing-remitting MS.
Market read
The call combines a guidance update with concrete pipeline and integration decisions, creating a clear catalyst set for repricing near-term expectations.
What to watch
Interest expense and foregone interest income from financing the Apellis deal could pressure future earnings quality even if revenue trends improve; also, the BIIB091 pause may reflect competitive dynamics that could affect pipeline confidence beyond MS.
Background
This is Biogen’s Q2 2026 earnings call transcript with product-by-product revenue updates, Apellis acquisition integration details, and pipeline execution commentary.
Ticker impact
Biogen reported Q2 2026 results and updated full-year guidance, including Apellis integration impacts and a pause of BIIB091 advancement.
Near-term volatility likely around guidance and the BIIB091 pause, with longer-term focus on growth portfolio momentum and felzartamab/litifilimab timing.
The article includes multiple new quantitative datapoints (revenue, EPS, FCF, net debt, guidance ranges) plus a concrete program decision (pause BIIB091) and updated regulatory/product execution details (LEQEMBI at-home initiation).
Market effects
Signals competitive pressure in MS and potential read-through for other neurodegenerative and immunology programs, especially around BTK inhibitor strategy.
No explicit regional macro impact; product execution and conversion rates are discussed across U.S., Europe, and Japan.
International launch progress (e.g., SKYCLARYS, ZURZUVAE) and global end-market sales trends may influence sentiment toward global specialty pharma demand.
Counterpoint
The headline GAAP EPS collapse may overstate underlying operating health because non-GAAP EPS declines are attributed to dilution and milestone charges, while revenue guidance is revised upward.
Key entities
- companyBiogen Inc.
Reported Q2 2026 financials, updated full-year guidance, discussed Apellis integration, and paused BIIB091 advancement.
- transactionApellis acquisition
Integration described with run-rate savings target and financing-related interest impacts.
- pipeline_programBIIB091
BTK inhibitor in relapsing-remitting MS, with advancement paused due to increasing market competitiveness.
- productLEQEMBI IQLIK
Subcutaneous at-home initiation approval discussed as reducing IV-related attrition.
- pipeline_programfelzartamab and litifilimab
Phase 3 readouts accelerated, with data now expected in 1H 2027.
